Cabazitaxel

BreastfeedingPediatric
  • TRADE NAME: Jevtana (Sanofi-Aventis)
  • INDICATIONS: Hormone-refractory metastatic prostate cancer (in combination with prednisone)
  • CLASS: Antineoplastic / anticancer agent, Microtubule inhibitor
  • HALF-LIFE: α-, β-, and γ-half-lives of 4 minutes, 2 hours, and 95 hours, respectively
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antineoplastics, Atazanavir, BCG Vaccine, Carbamazepine, Cardiac glycosides, Clarithromycin, Clozapine, Conivaptan, CYP3A4 inhibitors and inducers, Dasatinib, Deferasirox, Denosumab, Doxorubicin, Echinacea, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Leflunomide, Natalizumab, Nelfinavir, Phenobarbital, Phenytoin, Pimecrolimus, Rifabutin, Rifampin, Ritonavir, Saquinavir, Sipuleucel-T, St John's Wort, Tacrolimus, Telithromycin, Trastuzumab, Vaccines, Vitamin K antagonists, Voriconazole

PREGNANCY CATEGORY: D

NEUTROPENIC DEATH and SEVERE HYPERSENSITIVITY


See full prescribing information for complete boxed warning.

Our database has 54 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top